Progesterone from ovulatory menstrual cycles is an important cause of breast cancer
- PMID: 37254150
- PMCID: PMC10228093
- DOI: 10.1186/s13058-023-01661-0
Progesterone from ovulatory menstrual cycles is an important cause of breast cancer
Abstract
Many factors, including reproductive hormones, have been linked to a woman's risk of developing breast cancer (BC). We reviewed the literature regarding the relationship between ovulatory menstrual cycles (MCs) and BC risk. Physiological variations in the frequency of MCs and interference with MCs through genetic variations, pathological conditions and or pharmaceutical interventions revealed a strong link between BC risk and the lifetime number of MCs. A substantial reduction in BC risk is observed in situations without MCs. In genetic or transgender situations with normal female breasts and estrogens, but no progesterone (P4), the incidence of BC is very low, suggesting an essential role of P4. During the MC, P4 has a strong proliferative effect on normal breast epithelium, whereas estradiol (E2) has only a minimal effect. The origin of BC has been strongly linked to proliferation associated DNA replication errors, and the repeated stimulation of the breast epithelium by P4 with each MC is likely to impact the epithelial mutational burden. Long-lived cells, such as stem cells, present in the breast epithelium, can carry mutations forward for an extended period of time, and studies show that breast tumors tend to take decades to develop before detection. We therefore postulate that P4 is an important factor in a woman's lifetime risk of developing BC, and that breast tumors arising during hormonal contraception or after menopause, with or without menopausal hormone therapy, are the consequence of the outgrowth of pre-existing neoplastic lesions, eventually stimulated by estrogens and some progestins.
Keywords: Breast cancer; DNA replication; Estrogens; Menstrual cycles; Progesterone; Tumor doubling time; WNT4.
© 2023. The Author(s).
Conflict of interest statement
HJTCB is President, IJS is Director R&D and JK is Chief Medical Officer of Pantarhei Oncology (subsidiary of Pantarhei Bioscience), the company developing the fetal estrogen estetrol for the treatment of advanced breast and prostate cancer, but this is outside the scope of the present review. The other authors have nothing to disclose.
Figures
Comment in
-
Lack of evidence that progesterone in ovulatory cycles causes breast cancer.Climacteric. 2023 Dec;26(6):634-637. doi: 10.1080/13697137.2023.2249813. Epub 2023 Sep 6. Climacteric. 2023. PMID: 37671636
References
-
- NBCC Breast Cancer Facts & Figures. https://www.stopbreastcancer.org/information-center/facts-figures/ (accessed on April 11, 2022).
-
- Cancer Research UK. Breast cancer statistics. https://www.cancerresearchuk.org/health-professional/cancer-statistics/s... (accessed April 11, 2022).
-
- ACS. Key statistics for breast cancer in men. https://www.cancer.org/cancer/breast-cancer-in-men/about/key-statistics.... (accessed on April 11, 2022).
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
